Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.53 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.45 |
| ▸ | ABAT | P80404 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11660607 | 0.83 | ERN1 (0.55) | ERN1ABCB1ABCC1L3MBTL1MAPT | |
| SCHEMBL651066 | 0.81 | MAPT (0.64) | ERN1ABCB1ALDH1A1TSHRALOX15 | |
| SCHEMBL27861810 | 0.81 | ERN1 (0.53) | ERN1ABCB1ABCC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29465715 | 0.79 | KCNH2 (0.62) | ERN1ABCB1ABCC1MAPK1TSHR | |
| SCHEMBL1065088 | 0.79 | KCNH2 (0.62) | ERN1ABCB1ABCC1MAPK1TSHR | |
| SCHEMBL11661845 | 0.79 | ERN1 (0.51) | ERN1ABCB1ABCC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29484215 | 0.79 | MAPT (0.67) | MAPK1ALDH1A1SMN1; SMN2TP53HPGD | |
| SCHEMBL4368126 | 0.79 | MAPT (0.67) | MAPK1ALDH1A1SMN1; SMN2TP53HPGD | |
| SCHEMBL6469120 | 0.79 | MAPT (0.68) | ERN1MAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL10945034 | 0.78 | ERN1 (0.50) | ERN1ABCB1ABCC1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11596691-B2 | Photoswitchable HDAC inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| US-11596691-B2 | Photoswitchable HDAC inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210162048-A1 | Photoswitchable HDAC Inhibitors | THE GENERAL HOSPITAL CORPORATION | 2021-06-03 | — | — | US | disclosed |
| US-20210162048-A1 | Photoswitchable HDAC Inhibitors | THE GENERAL HOSPITAL CORPORATION | 2021-06-03 | — | — | US | disclosed |
| US-10828367-B2 | Photoswitchable HDAC inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-10828367-B2 | Photoswitchable HDAC inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190070295-A1 | Photoswitchable HDAC Inhibitors | THE GENERAL HOSPITAL CORPORATION | 2019-03-07 | — | — | US | disclosed |
| US-9981038-B2 | Photoswitchable HDAC inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981038-B2 | Photoswitchable HDAC inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| EP-1663953-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030705-A9 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030705-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | ERN1 1510/4885ABCB1 4043/4885ABCC1 3326/4885 |
| US-20190070295-A1 | Photoswitchable HDAC Inhibitors | HDAC4, HDAC1, HDAC3 | ERN1 3731/4885ABCB1 4084/4885ABCC1 4252/4885 |
| US-20210162048-A1 | Photoswitchable HDAC Inhibitors | HDAC4, HDAC1, HDAC3 | ERN1 3731/4885ABCB1 4084/4885ABCC1 4252/4885 |
| US-11596691-B2 | Photoswitchable HDAC inhibitors | HDAC4, HDAC1, HDAC3 | ERN1 3731/4885ABCB1 4084/4885ABCC1 4252/4885 |
| US-10828367-B2 | Photoswitchable HDAC inhibitors | HDAC4, HDAC1, HDAC3 | ERN1 3731/4885ABCB1 4084/4885ABCC1 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.